A bioassay of @entity5333 for possible carcinogenicity was conducted by administering the test chemical by intraperitoneal injection to @entity35 and B6C3F1 @entity19 . Groups of 35 @entity35 of each sex were administered @entity5333 at one of two doses, either 5 or 10 mg/kg body weight, three times per week for 52 weeks, then observed for an additional 31 or 32 weeks. The vehicle used for most of the period of the bioassay was 6% @entity2771 in saline, although other vehicles, including 0.05% @entity6496 80 in saline, were used at the beginning. Controls consisted of groups of 10 vehicle controls and 10 untreated controls of each sex. All surviving @entity35 were killed at 83-85 weeks. Groups of 35 @entity19 of each sex were administered @entity5333 at one of two doses, either 12.5 or 25 mg/kg body weight, three times per week for 50 or 52 weeks, then observed for an additional 31-33 weeks. Controls consisted of groups of 15 males and 15 females which were administered the vehicle (vehicle controls), and groups of 14 males and 16 females which were untreated (untreated controls). All surviving @entity19 were killed at 83-85 weeks. Mean body weights of the low-dose male @entity35 , low- and high-dose female @entity35 , and low-dose male and female @entity19 were comparable to those of the untreated and vehicle controls. The mean body weights of the high-dose male @entity35 and the high-dose male and female @entity19 , which died early, were lower than those of the controls. @entity6675 (peritoneum) was found in dosed animals of both species, but did not occur in either the untreated or vehicle controls. In male @entity35 , this lesion occurred with a significant dose-related trend (P>0.001), using a vehicle controls, and also at significant incidences in direct comparisons of the dosed groups with the vehicle controls (controls 0/10, low-dose 11/31, P=0.027; high-dose 16/20, P<0.001). In female @entity35 , the lesion occurred at a significant incidence in the high-dose group compared with the vehicle controls (controls 0/9, high-dose 16/30, P=0.004). None were observed among low-dose females. In the @entity19 , @entity242 of the abdominal cavity (peritoneum) occurred at a high and statistically significant incidence in the high-dose groups of each sex compared with vehicle controls (males: controls 0/15, high-dose 17/21, P<0.001; females: controls 0/13, high-dose 16/20, P<0.001). None were observed among low-dose groups. The morphology of the @entity242 was similar in the @entity35 and the @entity19 . It is concluded that under the conditions of this bioassay, @entity5333 was carcinogenic (sarcomagenic) for the peritoneum of both sexes of @entity35 and B6C3F1 @entity19 .

Bioassay of XXXX for possible carcinogenicity.

@entity2771 :: ('MESH:D019946', 'Chemical') :: ['propylene glycol'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma'] @entity6496 :: ('CHEBI:53426', 'Chemical') :: ['polysorbate'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity5333 :: ('MESH:D010643', 'Chemical') :: ['phenoxybenzamine hydrochloride'] @entity6675 :: ('MESH:D020139', 'Disease') :: ['Sarcoma of the abdominal cavity'] @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']
@entity5333 :: (MESH:D010643,Chemical) :: ['phenoxybenzamine hydrochloride']
